---
layout: post
title: "复星医药：重组人源抗PD-L1与抗TIGIT双特异性抗体注射液临床试验获批"
date: 2022-03-17 16:57:16 +0800
categories: emnews
tags: 东财滚动新闻
---
> 复星医药公告，公司子公司复宏汉霖药品HLX301(重组人源抗PD-L1与抗TIGIT双特异性抗体注射液)获药品临床试验批准。（财联社）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600196" data-code="600196|1|1" data-code2="600196|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600196&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600196_0" data-code="K 600196|1|1" data-code2="K 600196|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p><span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span><span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>，公司子公司<span id="Info.116.02696"><a href="http://quote.eastmoney.com/unify/r/116.02696" class="keytip" data-code="116,02696">复宏汉霖</a></span>药品HLX301(<span id="Info.3271"><a href="http://data.eastmoney.com/bgcz/" class="infokey">重组</a></span>人源抗PD-L1与抗TIGIT双特异性抗体注射液)获药品临床试验批准。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finance.eastmoney.com/news/1354,202203172314033048.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)